Moreover, combining CD47 blockade with other treatments, such as chemotherapy, monoclonal antibodies (e.g., rituximab for B-cell lymphomas), or immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), can further enhance anti-tumor efficacy. This evidence concerns the gene CD47 and neoplasm.